Plant Name: Forsythia viridissima
Taxonomic Information:
Plant ID: NPO19805
Plant Latin Name: Forsythia viridissima
Taxonomy Genus: Forsythia
Taxonomy Family: Oleaceae
Plant External Links:
NCBI TaxonomyDB:
205691
Plant-of-the-World-Online:
608903-1
Used in Medicines:
Country/Region:
South Korea; ChinaTraditional Medicine System:
TCMMedicinal Functions:
Antibacterial; Antifungal; Antispasmodic; Emmenagogue
Geographical Distribution:
United States; Japan; South Korea; China; South Africa
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| RECQL; ALOX12; HSD17B10; NOX4; POLB; | |
| ACHE; | |
| CDC25B; | |
| MET; AXL; FLT3; CDK1; PIM1; IGF1R; MAP2K1; KDR; AURKB; | |
| CA2; CA12; CA14; CA7; CA4; | |
| RORC; | |
| NR1H4; | |
| MMP9; MMP1; MMP2; | |
| TP53; NFKB1; | |
| LMNA; FABP4; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 | CHEMBL3587 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.764E-11 | 1.106E-06 | CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.003E-08 | 2.726E-05 | CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 3.579E-08 | 3.897E-05 | ALOX12, AURKB, AXL, CDK1, IGF1R, KDR, LMNA, MMP9, NFKB1, NR1H4, PIM1, TP53 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.422E-07 | 4.237E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.692E-07 | 4.653E-04 | CYP1A1, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.334E-06 | 6.755E-04 | AXL, FLT3, IGF1R, KDR, MAP2K1, MET |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.604E-06 | 7.764E-04 | CYP1A1, CYP1B1, CYP2C19, NOX4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.044E-06 | 9.271E-04 | CA12, CA2, CA4, CA7, MMP1, MMP2, MMP9, NR1H4, RORC, TP53 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 4.452E-06 | 1.829E-03 | ALOX12, CDC25B, CDK1, FLT3, IGF1R, KDR, MMP2, MMP9, PIM1, TSHR |
| BP | GO:0009987; cellular process | GO:0007569; cell aging | 7.094E-06 | 2.710E-03 | CDK1, MAP2K1, NOX4, TP53 |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 7.944E-06 | 2.932E-03 | ALOX12, CA12, CA2, CA7, FABP4, MET, NOX4, NPSR1, NR1H4, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 8.403E-06 | 2.999E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.403E-06 | 2.999E-03 | CYP1A1, CYP1B1, CYP2C19 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 8.598E-06 | 3.020E-03 | IGF1R, MMP2, NFKB1, NOX4, NR1H4, TP53, TSHR |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.070E-05 | 3.584E-03 | CA2, CA7 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 1.781E-05 | 4.971E-03 | ALOX12, IGF1R, KDR, MET, MMP9, NOX4, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 2.923E-05 | 7.071E-03 | CA2, CDK1, CYP1A1, FABP4, MMP9, TP53 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 3.422E-05 | 7.844E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008152; metabolic process | GO:0072593; reactive oxygen species metabolic process | 4.233E-05 | 8.950E-03 | ALOX12, CYP1A1, CYP1B1, NOX4 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.326E-08 | 1.563E-06 | MAP2K1, FLT3, MMP1, MMP2, MET, TP53, MMP9, NFKB1, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 9.959E-11 | 1.404E-08 | CA12, CA2, CA4, CA7, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.168E-08 | 8.235E-07 | MAP2K1, MMP1, MMP2, MMP9, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 7.959E-08 | 2.244E-06 | MAP2K1, MMP2, KDR, TP53, MMP9, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 5.717E-08 | 2.015E-06 | MAP2K1, PIM1, CYP1B1, TP53, MMP9, MET, NFKB1, CDC25B |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 9.015E-07 | 2.119E-05 | FLT3, TP53, MMP9, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.650E-06 | 7.352E-05 | MAP2K1, FLT3, PIM1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 8.813E-06 | 1.381E-04 | MAP2K1, TP53, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 6.989E-06 | 1.232E-04 | MAP2K1, FLT3, TP53, MET |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.163E-05 | 3.049E-04 | MAP2K1, TP53, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.499E-05 | 4.111E-04 | MAP2K1, KDR, TP53, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 3.162E-05 | 4.053E-04 | MAP2K1, CDK1, CDC25B, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 5.843E-05 | 6.337E-04 | MAP2K1, KDR, MET, NFKB1, IGF1R |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.270E-04 | 1.193E-03 | MAP2K1, LMNA, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.492E-04 | 1.315E-03 | MAP2K1, TP53, MMP9, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.076E-04 | 1.084E-03 | CYP1A1, CYP1B1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.352E-04 | 1.928E-03 | MAP2K1, TP53, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.461E-04 | 1.928E-03 | MAP2K1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 5.432E-04 | 3.481E-03 | POLB, CDK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 3.316E-04 | 2.461E-03 | MAP2K1, TP53, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 5.139E-04 | 3.450E-03 | MAP2K1, KDR, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 6.053E-04 | 3.711E-03 | MAP2K1, KDR, MET, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 8.574E-04 | 4.477E-03 | MMP2, PIM1, NFKB1 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 6.958E-04 | 4.088E-03 | TP53, NFKB1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 8.090E-04 | 4.459E-03 | MAP2K1, MMP2, MMP9 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.668E-04 | 3.291E-03 | CYP1A1, CYP1B1, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 1.225E-03 | 5.570E-03 | MAP2K1, TP53, NFKB1, CDC25B |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.098E-03 | 5.337E-03 | MAP2K1, MMP9, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 9.075E-04 | 4.570E-03 | MAP2K1, NFKB1, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.156E-03 | 5.435E-03 | MAP2K1, ALOX12, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.410E-03 | 5.849E-03 | MAP2K1, TP53, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 1.514E-03 | 6.069E-03 | MAP2K1, CDK1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.410E-03 | 5.849E-03 | MAP2K1, TP53, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04110 | Cell cycle | 1.550E-03 | 6.069E-03 | CDK1, TP53, CDC25B |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 1.310E-03 | 5.773E-03 | MAP2K1, TP53 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.485E-03 | 9.470E-03 | CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 8.221E-04 | 4.459E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TP53; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ACHE; MMP9; TP53; MMP2; CDC25B; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; TP53; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; MMP9; TP53; MMP2; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
